Preliminary Program
Session times on those days will not be finalized until the overall program schedule is completed.
Program Tracks (Please click each Track for detailed program information) |
Track 2: Breakthroughs in Cancer Prognostics and Diagnostics |
Track 2: Breakthroughs in Cancer Prognostics and Diagnostics
Track 2-1: Cancer Prognostic Biomarkers and Predictive Factors
| Time: May 15, 2019 (Wednesday) Place: Takasago, 4th Floor |
|
|
Chair |
Dr. Mu Wang, Professor, Xi'an Jiaotong-Liverpool University, China |
|
Co-chair |
Dr. Maria A. Nagai, Associate Professor, University of Sao Paulo, Brazil |
|
13:30-13:35 |
Chair's Introduction |
|
13:35-13:55 |
Title: Novel Molecular Subtypes to Predict Outcome to Bevacizumab in Metastatic Colorectal Cancer (mCRC) |
|
13:55-14:15 |
Title: Proteomic Characterization of Plasma Cells from Patients with Multiple Myeloma |
|
14:15-14:35 |
Title: Evaluation of PHLDA Gene Family Members as Prognostic and Predictive Biomarkers in Breast Cancer |
|
14:35-14:55 |
Title: HER2 Testing in Breast Cancer – Recent Updates on HER2 Interpretation of “Equivocal” Results |
| 14:55-15:15 |
Title: PDGFRA – PRKG2 Fusion Gene Serves as a Potential Biomarker that Predicts Good Clinical Outcomes in Myeloproliperative Neoplasm Unclassifiable |
|
15:15-15:30 |
Coffee Break |
|
15:30-15:50 |
Title: IL-21 and Schistosomiasis Associated Colorectal Cancer |
|
15:50-16:10 |
Title: Matrix Metalloproteinase and its Correlation with Stress Hormones in Lung Cancer Patients |
|
16:10-16:30 |
Title: The Study on Protein Microarray for Detection of Hepatocellular Carcinoma Biomarkers
Dr. Aiying Zhang, Professor, Beijing Institute of Hepatology, Beijing You-An Hospital, Capital Medical University, China |
| 16:30-16:50 | Title: HrC: A Novel Diagnostic and Prognostic Marker of Cancer Dr. Ashish Tripathi, CEO, Epigeneres Biotech Pvt Ltd., India |
| 16:50-17:10 | Title: Breast Cancer Distress Codex Interview for Recently Diagnosed Patients Dr. Marinella Linardos, Psycho-Oncologist, Catholic University of Rome , Italy |
| 17:10-17:30 | Title: The Role of Carnitine System in Cancer Metabolism Dr. Gianfranco Peluso, Research Director, Italian National Research Council, Italy |
Track 2-2: New Technological US, CT, MR Advances and Other Emerging Cancer Diagnostic Technologies and Tests
|
Time: May 16, 2019 (Thursday) |
|
|
Chair |
Dr. Philip Andrew Doble, Professor, University of Technology Sydney, Australia |
| Co-Chair | Dr. Elena Zyablova, Professor, S. V. Ochapovsky Regional Clinical Hospital, Russia |
|
09:00-09:05 |
Chair's Introduction |
|
09:05-09:30 |
Title: Distributions of Manganese in Diverse Human Cancers Provide Insights into Tumour Radioresistance |
| 09:30-09:55 |
Title: Blood-Flow Indices in Breast-Cancer Patients Receiving Chemotherapy |
|
09:55-10:20 |
Title: SwissMTB: Establishing Comprehensive Molecular Cancer Diagnostics in Swiss Clinics |
| 10:20-10:45 |
Title: Prostate Random Biopsy versus Targeted Biopsy |
|
10:45-11:00 |
Coffee Break |
| 11:00-11:25 |
Title: CT Angiography of The Chest in Patients with Central Lung Cancer |
| 11:25-11:50 |
Title: The Differential Diagnosis of Breast Cancer by the New Concept of Full Breast Ultrasonography. Changes in the Initial Evaluation of the Disease’s Extension |
| 11:50-12:15 |
Title: Clinical and Radiological Characterization in Ewing Sarcoma Family Tumors; 5 Years of Experience |
| 12:15-12:40 |
Title: Optimized HCC-specific Gene Therapy Based on Telomerase-Specific Targeting and Replacement by Trans-Splicing Ribozyme, Enhanced with Post-Transcriptional and MicroRNA Regulation |
BIT Group Global Ltd.
Japan-China Business Co., Ltd.
日中商務株式会社
Dr. Vladimir Lazar
Chief Scientific and Operating Officer
WIN Consortium, France
Dr. Ashok Srivastava
Chief Executive Officer & Chief Medical Officer, ClinFomatrix, Cure Pharmaceuticals, Inc, USA
Add: East Area, F11, Building 1, Dalian Ascendas IT Park, 1 Hui Xian Yuan, Dalian Hi-tech Industrial Zone, LN 116025, China]
Tel: 0086-411-84799609, Fax: 0086-411-84796897
Copyright © 2008-2019 BIT Congress Inc.